Study S003358

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

ClinicalTrials.gov record

Registration

Registration: NCT07017179
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 16
Start: 2025-05-20
Primary completion: 2026-10-23
Lead sponsor: AstraZeneca
Conditions: Obesity/Overweight
Interventions: DRUG:AZD6234; DRUG:Placebo; DRUG:AZD9550; DRUG:Plocebo; DRUG:AZD6234 in combination with AZD9550
Results posted: FALSE

Registered primary outcomes

Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1). [From baseline to Day 141]
Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2). [From baseline to Day 225]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.